Bruker Corporation (BRKR)
BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
Bruker beats Q1 earnings and revenue estimates as Europe growth and strong BSI bookings offset margin pressure and softer organic sales.
Bruker Corporation $BRKR Shares Purchased by Aquatic Capital Management LLC
Aquatic Capital Management LLC raised its holdings in shares of Bruker Corporation (NASDAQ: BRKR) by 120.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 349,596 shares of the medical research company's stock after buying an additional
Artisan Small Cap Fund Q4 2025 Portfolio Activity
During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.
Should You Continue to Hold BRKR Stock in Your Portfolio?
Bruker's innovation pipeline and acquisitions support long-term growth, but macro pressures and funding risks cloud the stock's near-term outlook.
BRKR Stock Up on the Launch of LUMOS II ILIM QCL-Based IR Microscope
Bruker launches LUMOS II ILIM QCL-based IR microscope for pharma and life science research.
New Strong Sell Stocks for November 12th
BRKR, CMC and CNXC have been added to the Zacks Rank #5 (Strong Sell) List on November 12, 2024.
BRKR Stock Declines Despite Launching EpicIF Technology for CellScape
Bruker's new technology, EpicIF, is set to enhance the CellScape Precise Spatial Proteomics platform.
BRKR Misses on Q3 Earnings, Cuts '24 View, Stock Up in Aftermarket
Bruker delivers robust revenue growth in the third quarter despite soft general market conditions.
BRKR Stock Might Gain From the Newly Launched OptoVolt Module
At the Neuroscience 2024 conference, Bruker released its latest OptoVolt module, which seamlessly integrates with Ultima 2Pplus microscope and NeuraLight 3D SLM.
Here's Why You Should Retain BRKR Stock in Your Portfolio Now
Bruker's robust growth potential across its Nano segment is encouraging. Yet, unfavorable currency movement is likely to pose a challenge.
Bruker (BRKR) Up 6.8% Since Last Earnings Report: Can It Continue?
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?
Should You Consider Retaining Bruker Stock in Your Portfolio Now?
BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.
